Table 5.
Open in new tab

Treatment persistence rates and biochemical parameters among patients switched to weekly or bi-weekly SC CT-P13 in patients on escalated intravenous infliximab dosing frequency prior to switch.

Every other week [n = 27]Weekly [n = 23]p-value
Treatment persistence rates
3 months100%96.3%0.353
6 months92.6%95.7%0.357
12 months92.6%95.7%0.650
C-reactive protein [mg/L]
Baseline3.0 [4.0]1.0 [2.0]0.014
3 months2.0 [4.0]1.0 [1.0]0.019
6 months2.5 [4.0]2.0 [1.0]0.112
12 months3.5 [4.0]1.0 [2.0]0.015
Faecal calprotectin [µg/g]
Baseline73.0 [1070.5]38.0 [125.0]0.782
3 months201.0 [193.0]36.0 [67.0]0.752
6 months79.0 [331.5]49.0 [121.0]0.476
12 months183.0 [306.5]30.0 [86.0]0.373
Infliximab levels [µg/dl]
Baseline11.9 [9.2]12.4 [8.7]0.338
3 months16.0 [2.6]16.0 [0.0]0.431
6 months16.0 [7.3]16.0 [0.0]0.909
12 months16.0 [2.4]16.0 [0.0]0.823
Every other week [n = 27]Weekly [n = 23]p-value
Treatment persistence rates
3 months100%96.3%0.353
6 months92.6%95.7%0.357
12 months92.6%95.7%0.650
C-reactive protein [mg/L]
Baseline3.0 [4.0]1.0 [2.0]0.014
3 months2.0 [4.0]1.0 [1.0]0.019
6 months2.5 [4.0]2.0 [1.0]0.112
12 months3.5 [4.0]1.0 [2.0]0.015
Faecal calprotectin [µg/g]
Baseline73.0 [1070.5]38.0 [125.0]0.782
3 months201.0 [193.0]36.0 [67.0]0.752
6 months79.0 [331.5]49.0 [121.0]0.476
12 months183.0 [306.5]30.0 [86.0]0.373
Infliximab levels [µg/dl]
Baseline11.9 [9.2]12.4 [8.7]0.338
3 months16.0 [2.6]16.0 [0.0]0.431
6 months16.0 [7.3]16.0 [0.0]0.909
12 months16.0 [2.4]16.0 [0.0]0.823

SC, subcutaneous.

Table 5.
Open in new tab

Treatment persistence rates and biochemical parameters among patients switched to weekly or bi-weekly SC CT-P13 in patients on escalated intravenous infliximab dosing frequency prior to switch.

Every other week [n = 27]Weekly [n = 23]p-value
Treatment persistence rates
3 months100%96.3%0.353
6 months92.6%95.7%0.357
12 months92.6%95.7%0.650
C-reactive protein [mg/L]
Baseline3.0 [4.0]1.0 [2.0]0.014
3 months2.0 [4.0]1.0 [1.0]0.019
6 months2.5 [4.0]2.0 [1.0]0.112
12 months3.5 [4.0]1.0 [2.0]0.015
Faecal calprotectin [µg/g]
Baseline73.0 [1070.5]38.0 [125.0]0.782
3 months201.0 [193.0]36.0 [67.0]0.752
6 months79.0 [331.5]49.0 [121.0]0.476
12 months183.0 [306.5]30.0 [86.0]0.373
Infliximab levels [µg/dl]
Baseline11.9 [9.2]12.4 [8.7]0.338
3 months16.0 [2.6]16.0 [0.0]0.431
6 months16.0 [7.3]16.0 [0.0]0.909
12 months16.0 [2.4]16.0 [0.0]0.823
Every other week [n = 27]Weekly [n = 23]p-value
Treatment persistence rates
3 months100%96.3%0.353
6 months92.6%95.7%0.357
12 months92.6%95.7%0.650
C-reactive protein [mg/L]
Baseline3.0 [4.0]1.0 [2.0]0.014
3 months2.0 [4.0]1.0 [1.0]0.019
6 months2.5 [4.0]2.0 [1.0]0.112
12 months3.5 [4.0]1.0 [2.0]0.015
Faecal calprotectin [µg/g]
Baseline73.0 [1070.5]38.0 [125.0]0.782
3 months201.0 [193.0]36.0 [67.0]0.752
6 months79.0 [331.5]49.0 [121.0]0.476
12 months183.0 [306.5]30.0 [86.0]0.373
Infliximab levels [µg/dl]
Baseline11.9 [9.2]12.4 [8.7]0.338
3 months16.0 [2.6]16.0 [0.0]0.431
6 months16.0 [7.3]16.0 [0.0]0.909
12 months16.0 [2.4]16.0 [0.0]0.823

SC, subcutaneous.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close